# LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer

> **NCT00005858** · PHASE1 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 25 (actual)

## Conditions studied

- Bladder Cancer
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** LMB-9 immunotoxin

## Key facts

- **NCT ID:** NCT00005858
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** 2003-12
- **Final completion:** 2003-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005858, "LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT00005858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*